“…In mammals (Dai et al, 2004;Bhalla et al, 2008;Xue et al, 2010;Voleti et al, 2017), Ca 2+ binding to the C2B domain of synaptotagmin 1 is crucial for synchronous release (Mackler & Reist, 2001;Mackler et al, 2002;Nishiki & Augustine, 2004;Shin et al, 2009;Bacaj et al, 2013;Lee et al, 2013), probably because the C2B domain has significantly higher sensitivity to Ca 2+ (Bradberry et al, 2020) and phospholipid-binding activity (Bai et al, 2004;Li et al, 2006;van den Bogaart et al, 2012;Bradberry et al, 2020) than the C2A domain in this protein. Indeed, all mutations in synaptotagmin 1 that cause diseases in humans target the C2B domain (Baker et al, 2018;Bradberry et al, 2020), while removal of the residues critical for Ca 2+ binding in the C2A domain is relatively innocuous (Stevens & Sullivan, 2003).…”